CTOs on the Move

Lattice Semiconductor

www.latticesemi.com

 
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world. Lattice was founded in 1983 and is headquartered in Hillsboro, Oregon with major operations in San Jose, California, Shanghai, China, and Manila, Philippines.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Tim Meier
 Senior. Director Information Technology and Chief Information Officer Profile

Similar Companies

High Connection Density Inc

High Connection Density Inc is a Sunnyvale, CA-based company in the Computers and Electronics sector.

Tvia, Inc.

Tvia, Inc. is one of the leading companies in the Computers and Electronics sector.

Grace Semiconductor

Grace Semiconductor is a Milpitas, CA-based company in the Computers and Electronics sector.

Lintech Components

Lintech Components is a Ronkonkoma, NY-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.